304 related articles for article (PubMed ID: 31083638)
1. Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Giannone G; Tuninetti V; Ghisoni E; Genta S; Scotto G; Mittica G; Valabrega G
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31083638
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.
Balakrishnan A; Vyas A; Deshpande K; Vyas D
World J Gastroenterol; 2016 Feb; 22(7):2159-64. PubMed ID: 26900281
[TBL] [Abstract][Full Text] [Related]
3. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
4. Targeting cyclin-dependent kinases in anti-neoplastic therapy.
Bruyère C; Meijer L
Curr Opin Cell Biol; 2013 Dec; 25(6):772-9. PubMed ID: 24011867
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Blachly JS; Byrd JC; Grever M
Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
[TBL] [Abstract][Full Text] [Related]
6. A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors.
Akin S; Babacan T; Sarici F; Altundag K
J BUON; 2014; 19(1):42-6. PubMed ID: 24659641
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
8. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography.
Nandi S; Dey R; Dey S; Samadder A; Saxena AK
Anticancer Agents Med Chem; 2022; 22(3):485-498. PubMed ID: 34503422
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase inhibitors for the treatment of lung cancer.
Qin A; Reddy HG; Weinberg FD; Kalemkerian GP
Expert Opin Pharmacother; 2020 Jun; 21(8):941-952. PubMed ID: 32164461
[TBL] [Abstract][Full Text] [Related]
10. Targeting cyclin-dependent kinases in gastrointestinal cancer therapy.
Zhang J; Su G; Lin Y; Meng W; Lai JKL; Qiao L; Li X; Xie X
Discov Med; 2019 Jan; 27(146):27-36. PubMed ID: 30721649
[TBL] [Abstract][Full Text] [Related]
11. CDK inhibitors from past to present: A new wave of cancer therapy.
Mughal MJ; Bhadresha K; Kwok HF
Semin Cancer Biol; 2023 Jan; 88():106-122. PubMed ID: 36565895
[TBL] [Abstract][Full Text] [Related]
12. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase modulators and cancer therapy.
Gallorini M; Cataldi A; di Giacomo V
BioDrugs; 2012 Dec; 26(6):377-91. PubMed ID: 22928661
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
16. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians.
Monaco EA; Vallano ML
Curr Med Chem; 2003 Mar; 10(5):367-79. PubMed ID: 12570697
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future.
DiPippo AJ; Patel NK; Barnett CM
Pharmacotherapy; 2016 Jun; 36(6):652-67. PubMed ID: 27087139
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Malínková V; Vylíčil J; Kryštof V
Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of the Cyclin-Dependent Kinase and PIM Kinase Pathways in the Treatment of Myeloma.
Ramakrishnan VG; Kumar SK
Cancer J; 2016; 22(1):7-11. PubMed ID: 26841010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
